Scope Ophthalmics partners with TearLab[London 17th September 2015]
Scope Ophthalmics, a leading player in the UK ocular surface disease market has partnered with TearLab to commercialise the first objective and quantitative diagnostic device for dry eye disease (DED).
Tom Freyne Scope Ophthalmics Director states: “We are delighted to partner with TearLab in the UK and Ireland. By adding a diagnostics dimension to the existing strong portfolio of Dry Eye Disease and Blepharitis products it ensures that the patient is receiving the right treatment for their condition.”
TearLab provides objective and quantitative testing for disease markers in tears at the point-of-care. The TearLab Osmolarity System allows clinicians to measure the osmolarity of human tears, helping to diagnose and manage patients suspected of having dry eye disease. TearLab is easy to use and takes a tiny amount of tears to diagnose. Peer-reviewed and published research has established osmolarity testing as an important tool in dry eye diagnosis and management.
“TearLab correlates best with patient symptoms and addresses many of the limitations we find with existing dry eye tests by providing quantitative, cut-off values that speed-up the diagnostic process,” explains Arthur Cummings, Consultant Eye Surgeon at the Wellington Eye Clinic and Consultant Ophthalmologist and Chair of the Department of Ophthalmology at the Beacon Hospital, Dublin. “Taking care of dry eye prior to cataract and refractive surgery provides better patient outcomes. TearLab can also be used to manage and monitor dry eye disease following cataract and refractive surgery and thereby facilitate the best possible post-operative care.”
“We are very excited about this new partnership,” explains Paul Smith, Vice President of International Markets from TearLab. “Scope Ophthalmics has a strong customer network and excellent distribution channels in the ocular surface area making them ideally placed to market the TearLab device.”
Operating in the optics, hospital and primary care channels, Scope will be adding a team of four to their existing sales team, including three TearLab specialists and a Business Unit Manager to ensure they bring this innovative technology to new and existing stakeholders.
For trade enquiries contact Scope Ophthalmics on +44 (0)800 270 0253 www.ScopeOphthalmics.com
For all media enquiries, contact Beth Lowes on 020 8995 5832 / Beth@ROADCommunications.co.uk
Dry eye disease affects 15% of the population but is likely to be under diagnosed¹. Studies have shown DED is detrimental to patients’ quality of life, and causes pain, reduced productivity at work, and difficulty carrying out everyday tasks, such as driving and reading².
About Scope Ophthalmics
Scope Ophthalmics (www.scopeophthalmics.com) is an innovative and fast-growing eye care company offering dry eye and blepharitis products in the UK and Ireland. All of its products have had long-term success with patients worldwide. The company maintains a major focus on training, customer service, innovation and relationships with key opinion leaders.
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity® Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System.
1. Dry Eyes Factsheet (2014) Royal College of General Practitioners
2. Dry Eye Disease: Impact on Quality of Life and Vision (2013) Uchino and Schaumberg. Current Opthalmology Reports 1(2): 51-57